-+ 0.00%
-+ 0.00%
-+ 0.00%

ALNYLAM PHARMACEUTICALS - PHASE 1B RESULTS SHOW 60-64% MEAN REDUCTION OF CSF MUTANT HUNTINGTIN AT MONTH 3

Reuters·10/23/2026 07:47:01